Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
07:30am, Thursday, 08'th Jul 2021
PALO ALTO, Calif., July 8, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines
Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
12:44pm, Wednesday, 30'th Jun 2021
Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:35pm, Monday, 14'th Jun 2021
PALO ALTO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medici
2 Top Biotech Stocks to Buy for Summer 2021
06:31am, Saturday, 05'th Jun 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
05:31pm, Tuesday, 01'st Jun 2021
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.
FDA Approves BridgeBio Pharma's FGFR2 Inhibitor for Bile Duct Cancer
08:02am, Tuesday, 01'st Jun 2021
BridgeBio Pharma Inc (NASDAQ: BBIO), through its affiliate QED Therapeutics Inc and Helsinn Group, has announced FDA approval for Truseltiq (infigratinib) under the accelerated approval program
BridgeBio Pharma Receives FDA Fast Track Designation for Encaleret for the Treatment of Autosomal Dominant Hypocalcemia Type 1
07:30am, Tuesday, 01'st Jun 2021
PALO ALTO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medi
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harbor
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 14'th May 2021
PALO ALTO, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 4, 2021,
BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia
07:30am, Friday, 14'th May 2021
- Preclinical Data for Congenital Adrenal Hyperplasia and Canavan Disease Programs Shared at American Society of Gene & Cell Therapy Annual Meeting, Enabling Anticipated Clinical Trials This Year - Pr
BridgeBio Pharma Stock Forecast: A Long-Term Buy Or Sell
11:20am, Monday, 03'rd May 2021
2021 is set to be a pivotal year for BridgeBio Pharma with several catalysts across a growing pipeline of candidate genetic medicines. The company's unique R&D strategy based on partnerships with acad
Andreas Halvorsen Takes Stake in Mudrick Capital Acquisition Following Merger Announcement
12:35pm, Wednesday, 21'st Apr 2021
Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition co
PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate resea
PALO ALTO, Calif. and SACRAMENTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with the University of California, Davis (UC Davis),
PALO ALTO, Calif. and BUFFALO, N.Y., April 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a collaboration with Roswell Park Comprehensive Cancer Center to advance t
